Flex Pharma Presenting at BIO CEO on February 13, 2018
February 06 2018 - 12:00PM
Business Wire
Click to Tweet
Flex Pharma, Inc. (NASDAQ: FLKS), a clinical-stage biotechnology
company that is developing innovative and proprietary treatments
for cramps and spasticity associated with severe neurological
diseases such as amyotrophic lateral sclerosis (ALS) and multiple
sclerosis (MS) and peripheral neuropathies such as
Charcot-Marie-Tooth (CMT), today announced that it will present at
the BIO CEO conference in New York, NY on February 13, 2018.
A live webcast of Flex Pharma’s presentations at these
conferences may be accessed in the Investor section of the
Company’s website at www.flex-pharma.com. Please log on to the Flex
Pharma website approximately 15 minutes prior to the scheduled
webcast to ensure adequate time for any software downloads that may
be required. A replay of the webcast will be available on Flex
Pharma’s website for 2 weeks following each presentation.
About Flex PharmaFlex Pharma, Inc. is a clinical-stage
biotechnology company that is developing innovative and proprietary
treatments in Phase 2 randomized, controlled trials for cramps and
spasticity associated with the severe neurological diseases of ALS,
MS and peripheral neuropathies such as Charcot-Marie-Tooth (CMT).
The Company’s lead candidate, FLX-787, is being developed under
Fast Track designation for the treatment of severe muscle cramps
associated with ALS. Flex Pharma was founded by National Academy of
Science members Rod MacKinnon, M.D. (2003 Nobel Laureate), and
Bruce Bean, Ph.D., recognized leaders in the fields of ion channels
and neurobiology, along with Christoph Westphal, M.D., Ph.D.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20180206005987/en/
Flex Pharma, Inc.Elizabeth Woo, 617-874-1829SVP, Investor
Relations & Corporate Communicationsirdept@flex-pharma.com
FLEX PHARMA, INC. (NASDAQ:FLKS)
Historical Stock Chart
From Mar 2024 to Apr 2024
FLEX PHARMA, INC. (NASDAQ:FLKS)
Historical Stock Chart
From Apr 2023 to Apr 2024